SYK

A comparison of two medical products sector stocks reveals Phibro Animal Health (PAHC) as the superior value opportunity. PAHC holds a Zacks Rank #1 (Strong Buy) with a forward P/E of 11.12 and Value grade of B, while Stryker (SYK) has a Zacks Rank #4 (Sell) with a forward P/E of 20.39 and Value grade of D. PAHC's stronger earnings outlook and more attractive valuation metrics make it the better choice for value investors.

Procter & Gamble and Stryker are recommended as long-term dividend stocks. P&G has increased dividends for 70 consecutive years with stable cash flow from consumer brands, while Stryker benefits from growing demand for medical devices driven by an aging population. Both offer different paths to wealth building through consistent dividend growth.

As AI dominates investment focus, healthcare and waste management sectors offer alternative diversification opportunities. Healthcare benefits from an aging population and rising medical needs, while waste management provides recurring revenue from essential services. Key companies like Abbott, Johnson & Johnson, Stryker, Waste Management, and Republic Services are positioned to capitalize on these structural trends.

Stryker announced a $400 million preferred equity investment in CMR Surgical, gaining exclusive U.S. sales rights for the Versius robotic surgery platform and an option to acquire the company. The deal allows Stryker to expand into soft-tissue robotics, complementing its existing Mako orthopedic platform, while CMR Surgical retains global commercialization rights outside the U.S.

ResearchAndMarkets.com released a comprehensive market report on Australia's stretchers and cots sector, covering ambulance cots, emergency stretchers, manual and motorized transport stretchers through 2033. The report provides revenue forecasts, volume data, pricing analysis, and competitive landscape insights for manufacturers, healthcare suppliers, and investors. Key companies analyzed include Stryker Corp, Hill-Rom Holdings Inc, International Biomedical Ltd, and Linet Group SE.

Pomerantz LLP is investigating Stryker Corp. for potential securities fraud following the CEO's disclosure on September 8, 2026, that a manufacturing problem in the peripheral vascular business would persist into Q4 2026 instead of resolving in Q3 as previously stated. The announcement triggered an 8.81% stock price decline, falling $26.70 per share to $276.43.

In a comparison of two medical products stocks, GE HealthCare Technologies (GEHC) emerges as the more attractive option for value investors compared to Stryker (SYK). GEHC has a higher Zacks Rank (#2 Buy vs #3 Hold), lower forward P/E ratio (12.97 vs 18.23), and a lower P/B ratio (2.63 vs 4.36), earning a Value grade of B compared to SYK's C grade.

The Equipment Leasing & Finance Association (ELFA) announced that James Cress, its Immediate Past Chair, will serve as Acting President & CEO while the board searches for a permanent replacement following Leigh Lytle's departure later in 2026. Cress brings over 30 years of banking and equipment finance experience, including 18 years at Stryker leading its captive finance business.

Intuitive Surgical (ISRG) is expected to report Q3 2026 earnings on October 20 with EPS projected at $2.61 (up 8.75%) and revenue growth of 15% to $2.88B. While the company benefits from international procedure growth and strong da Vinci 5 demand, it faces headwinds from moderating U.S. procedure growth, China pricing pressures, and higher costs. The stock trades at a premium valuation of 35.87X forward P/E, leaving limited room for disappointment.

Intuitive Surgical (ISRG) has gained nearly 12% in a month, outperforming the market ahead of Q3 earnings. The company benefits from strong da Vinci 5 adoption, growing Ion procedures, and expanding international markets.

However, slower U.S. procedure growth, GLP-1 drug competition affecting bariatric procedures, and China headwinds pose risks. ISRG trades at a premium 36.04X forward P/E but remains attractive with a Zacks Rank #2 (Buy) rating.

Johnson & Johnson's shares fell 5.8% after Q3 2026 results showed earnings beat but sales missed expectations. MedTech segment underperformed with only 2.5% growth due to Abiomed declines and international market challenges, while Innovative Medicine remained strong. Despite headwinds, J&J raised full-year guidance and targets over $100 billion in 2026 revenue with accelerated growth expected in 2027.

ASML faces a critical test of whether its leadership can maintain success after founders Martin van den Brink and CEO Peter Wennink retired in 2024. New CEO Christophe Fouquet has raised 2026 sales forecasts to €43-45 billion, but investors must assess whether the company's founder-driven culture persists. The article examines whether post-founder leadership can sustain Rule Breaker companies, using ASML's upcoming earnings report as a key indicator.

A comprehensive market report on China's stretchers and cots sector forecasts growth through 2033 across ambulance cots, emergency stretchers, manual and motorized transport segments. The report provides historical data from 2018, competitive analysis of key players, and strategic insights for market entry and investment decisions in the medical transport equipment sector.

Tilray Brands reported a quarterly loss of $0.32 per share, significantly worse than the consensus estimate of $0.19, representing a -68.42% earnings surprise. The company also missed revenue expectations, posting $257.15 million versus the estimate of $262.35 million. With unfavorable estimate revisions, Tilray received a Zacks Rank #5 (Strong Sell) rating and has underperformed the S&P 500 by 58.9% year-to-date.

Johnson & Johnson's MedTech segment experienced mixed results in Q2 2026, with growth slowing due to weaker Cardiovascular sales and declining Abiomed procedures, though Shockwave showed strong double-digit growth. The company expects improvement in H2 2026 driven by Vision, Orthopedics, and Surgery segments, but faces ongoing headwinds from China's VBP program and competitive pressures.

ResearchAndMarkets.com released a comprehensive market report on Spain's general hospital supplies sector, covering historical and forecast data from 2018 to 2033. The report analyzes market revenues, volumes, and pricing across key product segments including hospital beds, IV poles, exam tables, and surgical clippers, with 2025 competitive share data for major market players.

ResearchAndMarkets.com released a comprehensive market report on Canada's general hospital supplies sector covering 2018-2033. The report analyzes eight product segments including hospital beds, IV poles, exam tables, and surgical clippers, providing revenue, volume, and pricing data. It includes competitive positioning of key market players and identifies growth opportunities for manufacturers, suppliers, and investors in Canada's healthcare equipment market.